Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
NEW YORK - Tiziana Life Sciences Ltd. (NASDAQ:TLSA), a biotech firm focused on immunomodulation therapies with a market capitalization of $87 million, has announced promising preclinical results for its nasal anti-CD3 monoclonal antibody in treating spinal cord injuries (SCI). According to InvestingPro data, the company's stock has shown strong momentum with a 35% return over the past year, despite current profitability challenges. The studies demonstrated notable improvements in motor function when the preclinical model with SCI was treated with the nasal anti-CD3 antibody.
Spinal cord injuries are a significant health concern, affecting not only military service members but also the general population, with an estimated 300,000 individuals living with SCI in the U.S. and over 17,000 new cases reported annually. While pursuing this substantial market opportunity, InvestingPro analysis indicates the company maintains a moderate debt level with a debt-to-equity ratio of 0.1, though its current ratio of 0.85 suggests some liquidity constraints. Subscribers to InvestingPro can access 8 additional key insights about TLSA's financial position and growth prospects. The company's research points to the critical role of nasal anti-CD3 in modulating the inflammation caused by microglia, which is a key factor in the development of SCI.
Dr. Howard Weiner, Chairman of Tiziana's Scientific Advisory Board, stated that the pre-clinical findings underscore the importance of nasal anti-CD3 in controlling microglial inflammation associated with SCI. Dr. Saef Izzy, Associate Professor of Neurology at Harvard Medical (TASE:PMCN) School, also commented on the treatment's potential, noting the dampened microglial activation and marked improvements in motor function observed in the injured models.
The CEO of Tiziana Life Sciences, Ivor Elrifi, expressed the company's intention to expand the application of its nasal foralumab technology from neurologic diseases to spinal cord injury treatment. Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development and is currently being studied in a Phase 2a trial for non-active secondary progressive multiple sclerosis.
Tiziana's innovative nasal delivery approach aims to improve both the efficacy and safety of immunotherapy compared to intravenous administration. The company's patented technology is expected to have broad applications across its pipeline of therapies.
The information disclosed in this article is based on a press release statement from Tiziana Life Sciences. The forward-looking statements included in the press release reflect the company's views as of the announcement's date and involve risks and uncertainties that could cause actual results to differ materially from those projected. Based on InvestingPro's Fair Value analysis, the stock appears to be trading near its fair value, with an overall Financial Health score of "FAIR." Investors seeking deeper insights into TLSA's valuation metrics, financial health indicators, and growth potential can access comprehensive analysis through InvestingPro's advanced analytics platform.
In other recent news, Tiziana Life Sciences has made significant strides in the development of its immunotherapy treatments. The company's nasal anti-CD3 monoclonal antibody, foralumab, has shown potential in mitigating side effects of GLP-1 agonists, commonly used in metabolic disorder treatments. Tiziana's therapy aims to counter side effects of these agonists, potentially improving long-term patient outcomes.
In the field of neurodegenerative diseases, Tiziana's foralumab has been highlighted as a promising therapeutic option. A review article in Nature Reviews Neurology discussed the potential of intranasal foralumab in treating diseases such as Multiple Sclerosis (MS), Alzheimer’s disease, ALS, and Parkinson's disease.
Tiziana has also broadened its Phase 2 trial for MS therapy, with the FDA approving the inclusion of an additional 20 patients. Furthermore, 80% of the participants in an Expanded Access Program showed a reduction in microglial activity after six months of treatment with intranasal foralumab.
Tiziana was awarded a $4 million grant from the National Institutes of Health for Alzheimer's research, focusing on the potential use of intranasal foralumab as a therapy. Lastly, the company secured $3.4 million in non-dilutive funding to advance its Phase 2 clinical trial of intranasal foralumab for na-SPMS. These are the recent developments in Tiziana Life Sciences' ongoing operations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.